Completion of the second cohort of TEW-7197 and SMC decided to escalate to the next dose.
Jan 20, 2015EVENTSHit 3005
On 20th of Jan. 2015 (19th in USA) SMC reviewed safety of the second cohort (60 mg) of TEW-7197 (NCT02160106) and did not find any serious drug-related toxicity. The committee recommended a dose escalation to the next level (100 mg). Three clinical sites in the USA started recruitment of patients with solid tumor for the third cohort.
|Next||Announcement: 2nd annual general meeting of stockholders|
|Previous||Safety Monitoring Committee (SMC) reviewed safety of the first cohort of TEW-7197 and decided to escalate to the next dose.|